ReST Therapeutics is a Clinical Biotech leveraging its successful Seed Funding to advance our proprietary drug candidate through non-clinical testing and achieve the First in Human clinical study by end of 2023.
Our Mission
ReST develops breakthrough therapies to treat complex CNS disorders, in particular, various forms of Post-Traumatic Stress Disorder (PTSD) and Alzheimer’s Disease (AD). Our first candidate is Fluoro Ethyl Nor-Memantine (FENM), a new molecule selectively targeting NMDA receptors.
Management Team
Gilles Rubinstenn
Chief Operating Officer and GM France
Life Science Entrepreneur. Former Pharmaceutical BU director of M2I.
Inventor of FENM activity. Experienced manager of strategic alliances and R&D research consortia.
Florent Perin-Dureau
Chief Medical Officer
Physician, anesthesiologist and intensivist. Former ANSM director for SNC products.
Expert in NMDAr structure and function. Specialist in regulatory affairs and clinical trial design.
Our Blog
Latest Articles
EMA endorses ReST FIH for FENM
ReST Therapeutics announces the endorsement by the European Medicine Agency (EMA) to enter the clinical phase and request First in Human (FIH)...
First Results on FENM published in International Journal of Neuropsychopharmacology
FENM appeared as a potent neuroprotective drug in an AD model, with a superior efficacy compared with Memantine and an absence of direct amnesic effect at higher doses.
USPTO grants ReST Therapeutic’s Patent on PTSD
On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD. ReST...
A new patent for Biotech ReST Therapeutics as part of its search for solutions against Post-Traumatic Syndrome and Alzheimer’s
On May 6, the National Institute of Intellectual Property (INPI) issued ReST Therapeutics and its academic co-owners (University of Montpellier,...
FENM for the prevention and treatment of stress-induced maladaptive behavior
Biological Psychiatry Published: May 09, 2021DOI: https://doi.org/10.1016/j.biopsych.2021.04.024...
FENM facilitates extinction learning without sensorimotor deficits
International Journal of Neuropsychopharmacology, 2021 Jul 14;24(6):519-531. https://doi.org/10.1093/ijnp/pyab007 Fluoroethylnormemantine, A Novel...
ReST Results on Alzheimer to be presented at AD/PD 2021
Dr. Tangui Maurice of Montpellier University and ReST’s scientific partner will present FENM results on Alzheimer during the upcoming 15th International Conference on Alzheimer’s and Parkinson’s Diseases
ReST Academic Parners
